QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
NASDAQ:ISEE

IVERIC bio - ISEE Stock Forecast, Price & News

$13.25
+0.44 (+3.43%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.81
$13.37
50-Day Range
$9.12
$13.25
52-Week Range
$8.37
$19.34
Volume
2.32 million shs
Average Volume
1.78 million shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.20

IVERIC bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
82.6% Upside
$24.20 Price Target
Short Interest
Healthy
6.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of IVERIC bio in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$240,500 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.49) to ($1.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

148th out of 1,293 stocks

Pharmaceutical Preparations Industry

58th out of 619 stocks

ISEE stock logo

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Stifel Nicolaus boosted their target price on IVERIC bio from $22.00 to $28.00 in a research report on Wednesday, May 4th. Guggenheim assumed coverage on shares of IVERIC bio in a research report on Wednesday, June 8th. They set a "buy" rating and a $30.00 price target for the company. Morgan Stanley upped their target price on shares of IVERIC bio from $25.00 to $30.00 and gave the company an "overweight" rating in a research note on Thursday, July 7th. Credit Suisse Group boosted their target price on shares of IVERIC bio to $24.00 in a research note on Friday, May 20th. Finally, Bank of America initiated coverage on IVERIC bio in a research report on Wednesday, June 8th. They issued a "buy" rating and a $18.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, IVERIC bio presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.20.

IVERIC bio Price Performance

IVERIC bio stock traded up $0.29 during mid-day trading on Monday, reaching $13.10. 93,418 shares of the stock traded hands, compared to its average volume of 1,780,960. The stock has a market capitalization of $1.55 billion, a PE ratio of -10.50 and a beta of 1.52. IVERIC bio has a 12-month low of $8.37 and a 12-month high of $19.34. The business's 50-day moving average is $10.64 and its 200-day moving average is $13.19.

IVERIC bio (NASDAQ:ISEE - Get Rating) last posted its quarterly earnings data on Tuesday, July 26th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). During the same quarter last year, the company earned ($0.32) earnings per share. Equities analysts anticipate that IVERIC bio will post -1.49 EPS for the current fiscal year.

Insider Activity

In related news, Director Calvin W. Roberts purchased 25,000 shares of the business's stock in a transaction dated Monday, June 13th. The shares were acquired at an average cost of $9.62 per share, for a total transaction of $240,500.00. Following the acquisition, the director now owns 32,500 shares of the company's stock, valued at approximately $312,650. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Christopher Paul Simms sold 12,272 shares of the business's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $11.25, for a total value of $138,060.00. Following the completion of the transaction, the senior vice president now owns 28,547 shares of the company's stock, valued at approximately $321,153.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Calvin W. Roberts acquired 25,000 shares of the business's stock in a transaction on Monday, June 13th. The shares were purchased at an average price of $9.62 per share, with a total value of $240,500.00. Following the completion of the purchase, the director now owns 32,500 shares in the company, valued at approximately $312,650. The disclosure for this purchase can be found here. Company insiders own 2.70% of the company's stock.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

IVERIC bio, Inc. (NASDAQ:ISEE) SVP Sells $138,060.00 in Stock
What 5 Analyst Ratings Have To Say About IVERIC bio
Short Volatility Alert: IVERIC bio, Inc.
Expert Ratings for IVERIC bio
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings
7/26/2022
Today
8/08/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.20
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+82.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-114,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.14 per share

Miscellaneous

Free Float
114,890,000
Market Cap
$1.56 billion
Optionable
Optionable
Beta
1.52














ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ISEE shares.
View ISEE analyst ratings
or view top-rated stocks.

What is IVERIC bio's stock price forecast for 2022?

10 brokers have issued 1-year price objectives for IVERIC bio's stock. Their ISEE stock forecasts range from $12.00 to $30.00. On average, they expect the company's share price to reach $24.20 in the next twelve months. This suggests a possible upside of 86.0% from the stock's current price.
View analysts price targets for ISEE
or view top-rated stocks among Wall Street analysts.

How has IVERIC bio's stock performed in 2022?

IVERIC bio's stock was trading at $16.72 at the beginning of 2022. Since then, ISEE shares have decreased by 22.2% and is now trading at $13.01.
View the best growth stocks for 2022 here
.

Are investors shorting IVERIC bio?

IVERIC bio saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 7,450,000 shares, a drop of 22.4% from the June 30th total of 9,600,000 shares. Based on an average daily volume of 2,090,000 shares, the days-to-cover ratio is presently 3.6 days.
View IVERIC bio's Short Interest
.

When is IVERIC bio's next earnings date?

IVERIC bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ISEE earnings forecast
.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) posted its quarterly earnings results on Tuesday, July, 26th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.10. During the same period last year, the company posted ($0.32) EPS.

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by many different retail and institutional investors. Top institutional investors include Candriam S.C.A. (1.24%), Silverarc Capital Management LLC (0.00%), Connor Clark & Lunn Investment Management Ltd. (0.29%), Thornburg Investment Management Inc. (0.24%), SG Americas Securities LLC (0.14%) and TD Asset Management Inc. (0.13%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends
.

How do I buy shares of IVERIC bio?

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $13.01.

How much money does IVERIC bio make?

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $1.54 billion. The company earns $-114,520,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does IVERIC bio have?

IVERIC bio employs 94 workers across the globe.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (212) 845-8200 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.